A Phase 3 interventional study of Zoledronic acid and Letrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 49 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing Zoledronic Acid in Breast Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Zoledronic Acid · Breast Neoplasms.
Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, this one is the 11th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2004, is one of 24 in phase 3, and was the 11th registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 59 studies testing Zoledronic Acid in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 27 · Phase 4 11
First in 1999; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 527 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 98 across the 56 interventional studies. Of the 52 that completed or were terminated, 21 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 20th largest by enrollment of the 155 interventional ones that give a count, is one of 2 that started in 2004, is one of 45 in phase 3, and was the 9th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion / exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
Drug: Zoledronic acid · Drug: Letrozole
Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
Drug: Zoledronic acid · Drug: Letrozole
Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
Also known as: ZOL446, Zometa®
Letrozole tablets 2.5 mg/day/taken orally for 5 years.
Also known as: Femara®
Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
Time frame: From Baseline - 12 months
Percent Change in Lumbar Spine (L2-L4) BMD at 2 Years, 3 Years, 4 Years and 5 Years
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
Time frame: From Baseline to Year 2, Year 3, Year 4, Year 5
Percent Change in Lumbar Spine (L1-L4) BMD at Year 1, Year 2, Year 3, Year 4 and Year 5
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
Time frame: From Baseline to Year 1, Year 2, Year 3, Year 4, Year 5
Percent Change in Total Hip BMD at Year 1, Year 2, Year 3, Year 4 and Year 5
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
Time frame: From baseline to Year 1, Year 2, Year 3, Year 4, Year 5
Percentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 3
Radiological Fracture at 36 months which was not present at baseline = (new fracture/number participant analyzed)\*100. Evaluation of radiological fractures were based on central lab X-ray data. A subject with multiple fractures at the same time or multiple fractures with the same grade is counted only once for that treatment.
Time frame: Year 3
| Milestone | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| Started | 263 | 264 |
| Safety population | 254 | 269 |
| Completed | 172 | 186 |
| Not completed | 91 | 78 |
| Withdrew: Adverse event | 44 | 41 |
| Withdrew: Lack of efficacy | 19 | 14 |
| Withdrew: Withdrawal by subject | 9 | 6 |
| Withdrew: Abnormal test procedure results | 9 | 3 |
| Withdrew: Protocol violation | 3 | 7 |
| Withdrew: Administrative problems | 4 | 3 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Death | 2 | 1 |
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
| Percent Change | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy | 2.680 ± 2.8451 | -3.314 ± 3.9632 |
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
| Percent Change | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| Year 2 (n=122,142) | 4.136 ± 3.8182 | -3.924 ± 4.7442 |
| Year 3 (n=119,133) | 4.777 ± 4.8959 | -4.297 ± 5.3583 |
| Year 4 (n=104, 122) | 5.462 ± 5.2922 | -4.746 ± 5.6588 |
| Year 5 (n=86, 102) | 6.013 ± 5.4366 | -4.572 ± 6.1617 |
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
| Percent Change | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| Year 1 (n=123, 156) | 2.330 ± 2.7465 | -3.532 ± 3.7830 |
| Year 2 (n=122, 142) | 3.994 ± 3.6344 | -3.934 ± 4.7162 |
| Year 3 (n=199, 133) | 4.523 ± 4.5197 | -4.292 ± 5.2317 |
| Year 4 (n=104, 122) | 5.051 ± 4.9739 | -4.713 ± 5.4101 |
| Year 5 (n=86, 102) | 5.476 ± 5.0395 | -4.692 ± 6.0242 |
Bone Mineral Density (BMD)is measured by dual energy x-ray absorptiometry (DXA).Percent Change = \[(BMD at Visit - BMD at Baseline) / BMD at Baseline\] \* 100.
| Percent Change | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| Year 1 (n=173, 187) | 1.637 ± 2.4371 | -1.644 ± 2.9994 |
| Year 2 (n=169, 168) | 2.119 ± 2.9435 | -2.628 ± 3.5659 |
| Year 3 (n=163, 162) | 1.991 ± 3.4207 | -3.011 ± 4.7684 |
| Year 4 (n=145, 152) | 2.439 ± 3.5236 | -3.074 ± 5.4515 |
| Year 5 (n=119, 121) | 2.788 ± 3.8386 | -4.012 ± 5.1321 |
Radiological Fracture at 36 months which was not present at baseline = (new fracture/number participant analyzed)\*100. Evaluation of radiological fractures were based on central lab X-ray data. A subject with multiple fractures at the same time or multiple fractures with the same grade is counted only once for that treatment.
| Percentage of Participants | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| Percentage of Participants With Radiological (Vertebra) Fractures Which Were Not Present at Baseline But Were Present at Year 3 | 2.8 | 3.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Upfront Zoledronic Acid | — | 47/254 (18.5%) | 225/254 (88.6%) |
| Delayed Zoledronic Acid | — | 56/269 (20.8%) | 240/269 (89.2%) |
| Event | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/254 | 5/269 |
| Cardiac failureCardiac disorders | 4/254 | 1/269 |
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 3/254 | 1/269 |
| Ovarian cystReproductive system and breast disorders | 3/254 | 1/269 |
| Angina pectorisCardiac disorders | 0/254 | 3/269 |
| FallInjury, poisoning and procedural complications | 2/254 | 3/269 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/254 | 3/269 |
| DepressionPsychiatric disorders | 0/254 | 3/269 |
| Myocardial infarctionCardiac disorders | 2/254 | 0/269 |
| Ankle fractureInjury, poisoning and procedural complications | 2/254 | 0/269 |
| Event | Upfront Zoledronic Acid | Delayed Zoledronic Acid |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 123/254 | 136/269 |
| Hot flushVascular disorders | 66/254 | 101/269 |
| FatigueGeneral disorders | 46/254 | 57/269 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 26/254 | 46/269 |
| Back painMusculoskeletal and connective tissue disorders | 41/254 | 36/269 |
| AstheniaGeneral disorders | 26/254 | 36/269 |
| MyalgiaMusculoskeletal and connective tissue disorders | 33/254 | 35/269 |
| Weight increasedInvestigations | 33/254 | 23/269 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 26/254 | 34/269 |
| HypertensionVascular disorders | 32/254 | 25/269 |
| Age Continuous(years) | Upfront Zoledronic Acid | Delayed Zoledronic Acid | Total |
|---|---|---|---|
| Mean | 58.2 ± 8.19 | 58.4 ± 7.73 | 58.29 ± 7.96 |
| Sex: Female, Male(Participants) | Upfront Zoledronic Acid | Delayed Zoledronic Acid | Total |
|---|---|---|---|
| Female | 263 | 264 | 527 |
| Male | 0 | 0 | 0 |
The record gives a start of Mar 2004 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zoledronic Acid · Letrozole